NATIONAL MARROW DONOR PROGRAM®

Dana Farber Cancer Institute: Center Specific Analyses

Adult Program

This analysis includes **ONLY** patients who received their **FIRST ALLOGENEIC*** transplant between January 1, 2008 and December 31, 2010 **using unrelated or related donors**, **and** who had at least a 100-day follow-up.

1. This center reported survival status data for **635** patients.
2. The **actual one-year survival** of these patients is **67%**.
3. Based on a national average for patients like those transplanted at this center, 95% of the time the one-year survival is **expected** to be between 60% and 67% for patients at this center.
4. This center's **actual** results are **similar to** the **expected** range for this center.

**Allogeneic means using cells from a person other than the patient.*
For help with understanding these statistics, please see Understanding Transplant Outcomes

Pediatric Program

This analysis includes **ONLY** patients who received their **FIRST ALLOGENEIC*** transplant between January 1, 2008 and December 31, 2010 **using unrelated or related donors**, **and** who had at least a 100-day follow-up.

1. This center reported survival status data for **137** patients.
2. The **actual one-year survival** of these patients is **79%**.
3. Based on a national average for patients like those transplanted at this center, 95% of the time the one-year survival is **expected** to be between 72% and 85% for patients at this center.
4. This center's **actual** results are **similar to** the **expected** range for this center.

**Allogeneic means using cells from a person other than the patient.*
For help with understanding these statistics, please see Understanding Transplant Outcomes